Aging of Receivables Analysis for Infusion Practice Finance Teams

Standard AR aging reports sort claims by how long they've sat unpaid, treating time as the main signal of risk. That's the wrong lens for infusion billing. A single claim can carry $10,000 to $50,000 in drug acquisition cost, and a 30/60/90-day bucket treats that claim the same as a $200 office visit sitting one row below it. Finance teams end up staring at a total balance with no way to tell whether the real exposure sits in a handful of biologic claims or spreads thin across hundreds of smaller ones.

Under buy-and-bill, the practice pays for the drug before the payer ever settles the claim. An aging claim isn't just unpaid, it's borrowed capital, and every extra day it sits unresolved is a day that money stays locked up funding someone else's treatment. A 45-day-old claim for a $40,000 biologic infusion lands in the same bucket as a 45-day-old claim for a $200 office visit. They don't carry the same risk, and any team that treats them the same is misreading its own exposure.

Aging reports start the clock at claim submission or date of service, then sort into buckets as adjudication drags on. That design does a few things well: it shows total outstanding balance by time band, gives a rough count of unresolved claims, and, weighed against average daily charges, offers a proxy for Net Days in AR.

What it doesn't show is where the risk actually lives. A $500 average balance can sit right next to ten $50,000 outliers that dominate the real exposure, and the report won't flag the difference. A denied claim and a pending claim can both land in the "60-90 days" bucket, even though one needs an appeal filed today and the other just needs time. Root cause disappears too: prior auth failure, coding error, eligibility lapse, and timely filing risk all look identical once claims are sorted by age alone. Payer behavior gets flattened the same way. A 45-day claim with one payer might be right on schedule; the same age with another payer could mean a stalled review, or an underpayment pattern building quietly underneath it. None of that shows up when elapsed time is the only variable doing the sorting.

By the time a denial shows up on the aging report, the decision that caused it, a missed auth renewal, a coding mismatch, a documentation gap, usually happened days or weeks earlier. The report is missing the problem. It's confirming, late, that something already went wrong upstream.

How denial volume and payer behavior inflate infusion AR in ways the buckets obscure

Denials have gotten more common, and pricier to work through. The share of providers seeing denial rates above 10% climbed from 30% in 2022 to 41% in 2025. That's a multi-year climb, not a blip, and infusion claims sit right in the path of it.

High-dollar service lines draw more scrutiny than the rest of the chart. Oncology, orthopedics, and infusion therapy face heavier manual payer review than lower-cost lines, mostly because the dollar amounts justify the extra look. Payers now run automated systems that flag claims before they're even paid, catching mismatched CPT and diagnosis pairs, odd utilization patterns, or vague codes. Denials can land within 24 to 48 hours of submission now, sometimes for reasons that weren't triggers a few years back.

Pre-payment audits add another wrinkle. Payers hold payment while reviewing documentation, tacking two to six weeks onto the timeline. Those claims still age normally on the standard report, but the practice has no clear next step until the audit resolves.

Prior authorization is the biggest single driver here, missing or invalid auth accounts for 20% to 25% of all denials. Eligibility and coverage issues run 15% to 20%, medical necessity disputes 10% to 12%, coding errors another 10% to 12%, and late submission 5% to 8%. Those aren't evenly weighted problems, and treating them as one lump "denials" category erases the difference between a five-minute fix and a lost claim.

Medicare Advantage compounds the unevenness further. MA denial rates vary meaningfully depending on the insurer. The same therapy, billed to two different MA plans, can age in completely different ways, and a blended aging total just averages that variation away instead of showing it. Roughly 65% of denials are recoverable, but only if worked inside the payer's appeal window, a detail the standard aging report never flags until that window's nearly shut.

The analytical dimensions that make infusion AR aging legible

Fixing this means keeping the aging report while addressing its shortcomings. It means layering it with dimensions that time alone can't capture, and treating age as one input among several instead of the whole picture.

Claim dollar size comes first, and it should probably come first on every finance team's dashboard, not buried three tabs deep. AR needs segmentation by value, not just by age, so high-dollar biologic and J-code claims get tracked on their own tier regardless of which time bucket they land in. A single denied biologic claim can tie up drug acquisition cost that a smaller practice can't absorb for months. A "top N by dollar" view sitting on top of the standard totals catches that in a way a blended average never will.

Claim status matters just as much. Pending, denied, underpaid, and appealed claims need separate treatment even within the same time band, because a pending claim moving through normal adjudication and a denied claim needing an appeal filed by Friday aren't the same problem, even at 47 days old each. Mixing those statuses into one bucket produces a number that looks clean but tells nobody what to do next.

Denial root cause deserves its own lens too. Prior auth failures, medical necessity disputes, coding errors, eligibility lapses, and timely filing risks each need a different fix, a different owner, a different prevention step. Lumping them all under "denied" hides the pattern, and the same CARC code can require entirely different appeal documentation depending on which payer issued it. A shared denial code doesn't mean a shared response.

Payer identity is its own dimension, not an afterthought. Average days to payment, denial rate, and appeal success rate should get tracked payer by payer, because a 45-day claim with a payer that typically runs 50-day cycles isn't the same risk as a 45-day claim with a payer whose norm is 20 days. Without that benchmark sitting next to the number, "45 days" can mean "on track" or "in trouble," and there's no way to tell which.

Therapy type and J-code round it out. Authorization complexity, denial probability, and drug cost exposure vary widely by therapeutic category, anti-infective therapies, biologics, and chemotherapy agents all carry distinct payer behavior and distinct stakes when a claim ages. Put these dimensions together, and a flat, time-elapsed snapshot turns into something closer to a risk-stratified work queue.

Reading prior authorization status as a leading indicator inside the aging report

Prior auth failures make up 20% to 25% of all denials industry-wide. For infusion specifically, auth problems are the single biggest driver pushing claims into the older buckets, and treating them as just another denial category misses what makes them different: they're predictable, and mostly preventable, in a way coding errors often aren't.

Authorization for recurring infusion therapy isn't a one-and-done event. Renewal windows vary by payer and by therapy, approval timelines keep stretching, and a lapse mid-cycle can make weeks of claims unrecoverable in one stroke. By the time an auth-related denial shows up in the 30-day bucket, the real problem probably started back at intake, at scheduling, or the moment a treatment plan changed. The billed claim didn't create the problem. It just revealed one that already existed.

A finance team reading auth status inside the aging report should watch a short list of specific things: how many claims aging past 30 days carry an auth denial code and are still inside the appeal window versus already past it, which therapies generate the most auth-lapse denials, what average payer turnaround looks like for auth decisions by drug category, and how often first-time auth submissions get denied. A high rate on that last one points to a documentation problem on the practice's own end, not payer friction.

Approval criteria for infusion drug authorizations are set to tighten further heading into 2026, so this pressure isn't easing off anytime soon. The stakes reach past finance, too: the AMA's 2024 Prior Authorization Physician Survey found 34% of physicians reported a serious adverse event tied to prior-auth delays. Auth tracking isn't a revenue exercise wearing a clinical disguise. Getting auth status visible inside the aging report gives clinical and billing staff the early signal they need to step in before a stalled auth turns into a written-off claim.

Identifying underpayments that hide inside "resolved" aging buckets

Once a payer sends a remit, even a partial one, the claim drops off the open AR report. It looks resolved. It isn't, and this is exactly where most finance teams lose visibility without ever noticing they've lost it.

Infusion underpayments come from a handful of repeatable mechanisms, not random error. Incorrect unit pricing is one: Part B drugs get reimbursed at 106% of ASP, and if a payer applies a lower rate or miscounts units, that gap is real money walking out the door, not a rounding difference. Missing add-on codes or modifiers are another. Infusion billing runs on hierarchical CPT coding, primary, sequential, concurrent, and a payer that collapses sequential infusion codes into the primary rate has underpaid the claim without ever flagging it as a denial. Contractual rate misapplication happens too, where a payer applies the wrong fee schedule or an outdated contract version, often with no exception noted anywhere on the remit. Site-of-care adjustments are becoming more common as well, where payers apply a lower rate on the argument that the service should've happened in a lower-acuity setting, again usually without saying so directly.

Without line-level reconciliation against expected payment, by drug, by CPT, by payer contract, these underpayments turn into permanent write-offs. They never re-enter an open bucket, so nothing ever triggers a second look. The fix is a separate "resolved but underpaid" work queue sitting apart from the standard aging report, built specifically to catch claims where money arrived but not the right amount of it. Coding errors generate just as many quiet underpayments as outright rejections. A partial payment on a miscoded infusion service is the same underlying failure as a denial. It's just harder to spot, because nobody's looking for it.

The 2026 Medicare Drug Price Negotiation Program adds a new wrinkle here. Starting in 2028, selected Part B drugs shift to reimbursement based on MFP rather than ASP. That's a fresh underpayment risk for any practice that doesn't update its expected-payment benchmarks well ahead of the change.

How to prioritize AR follow-up when every claim looks urgent

Infusion AR teams work against pressures stacked on top of each other: high claim volume, high average dollar value, short appeal windows, denial patterns that demand a different response depending on the payer. Everything looks urgent at once, which is exactly why working oldest-to-newest fails as a strategy. Age tells you nothing about whether money is actually recoverable, and recoverability is the only thing that should drive the queue.

The cost of getting this backwards is concrete. Reworking a denied claim runs $25 to $118. With only 65% of denials recoverable, and only inside the payer's appeal window, a misprioritized queue costs twice: once in wasted rework, once in write-offs on claims that simply aged past deadline while someone worked something older first.

A tiered approach beats working strictly oldest-to-newest. Tier one is high-dollar denied claims still inside their appeal window, worked first no matter what bucket they land in, because they carry the most money and the least time left on the clock. Tier two is auth-lapse denials on recurring therapies, where a delay threatens the patient's next treatment cycle as much as the current claim, meaning clinical and billing staff need to coordinate on the fix together rather than pass it back and forth. Tier three covers claims approaching the timely filing limit: a clean claim that slips past that deadline becomes unrecoverable no matter how strong the documentation is, and since late submission drives 5% to 8% of denials, most of this tier is preventable with earlier attention rather than faster appeals. Tier four is underpayments caught through remit reconciliation, no appeal clock ticking, but steadily eating margin if left alone, worked in batches on a set schedule. Tier five is low-dollar, low-complexity claims, better handled through automation and rules-based routing than manual review.

Denials need to get worked within seven days of landing. The average time from denial to resolution runs 60 to 90 days. That gap, between the window to catch a problem and the time it actually takes to close one out, is exactly why routing has to happen fast and right the first time. Payer-specific turnaround benchmarks belong inside the prioritization logic too: a claim that looks old by the calendar might be right on schedule for that particular payer, and the reverse holds just as often. The queue has to sort by what's actually recoverable, not by what's oldest on the page.

The metrics that tell finance teams whether their AR is improving or deteriorating

Net Days in AR remains the standard headline number, useful for spotting a trend over time. On its own, though, it blends payer types, claim sizes, and denial statuses into a single figure, which means it can mask a growing problem in one segment behind steady performance in another. Treating it as the whole story is the mistake most finance teams still make, and it's the one worth dropping first.

First-Pass Resolution Rate, the share of claims paid correctly on first submission with no rework needed, is the sharper leading indicator of the two. It reflects the health of everything upstream: intake accuracy, auth verification, coding precision, eligibility checks. A slipping FPRR shows a problem building before it ever surfaces as a wave of denials on the aging report weeks later.

Read alongside claim-size segmentation, payer-specific turnaround benchmarks, and a dedicated underpayment queue, these numbers give finance teams something a standard aging report never could: a real answer to whether the AR position is getting better, or just getting older. Ruby RCM, a revenue cycle management platform built exclusively for infusion centers and buy-and-bill practices that pairs billing software with hands-on operators to manage authorizations, claims, denials, and AR end to end, is one example of an operation structured around exactly that kind of visibility.